Price and states served both move. Read them off the seller's own site before you enroll.How our reviews work →

Alloy vs NowPatient

Alloy costs $900 less a month, and both sell semaglutide, tirzepatide and liraglutide.

Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more

By Ruth Calder · Enforcement Editor
Editorially reviewed (not clinically reviewed). Not medical advice · How we verify contentLast reviewed
Alloy logo

Alloy

6.2
★★★☆☆3.1/5

Best for: compounded semaglutide at $169/month

Visit Alloy →
VS
NowPatient logo

NowPatient

6.1
★★★☆☆3.1/5

Best for: an oral route if you will not self-inject

Visit NowPatient →

If you are choosing between Alloy and NowPatient, the first difference is cost: Alloy is $900 a month cheaper at the entry price. Both prescribe semaglutide, tirzepatide and liraglutide, so moving from one to the other would not change your drug. Alloy leads our six-part score, 6.2 to 6.1.

Alloy vs NowPatient price

Alloy is the cheaper way in: $169 a month against $1,069 a month at NowPatient. That is $900 less each month (84% lower), or about $10,800 over a year of treatment.

Drug by drug: Semaglutide is cheaper at Alloy ($169 a month vs $1,349 a month); tirzepatide is cheaper at Alloy ($199 a month vs $1,069 a month); liraglutide is cheaper at Alloy ($214 a month vs $1,349 a month).

Medications and formats

Both sell semaglutide, tirzepatide and liraglutide.

On format, Alloy prices compounded injections and brand-name pens, while NowPatient prices brand-name pens.

Where each one treats patients

Neither Alloy nor NowPatient publishes the states it serves, so enter your state at the very start of each sign-up.

Pricing

Alloy

Compounded semaglutide + Weight Care feeCompounded
$169/mo
semaglutide

$70 medication + mandatory $99/mo Alloy Weight Care fee = $169/mo effective

Compounded tirzepatide + Weight Care feeCompounded
$199/mo
tirzepatide

$100 medication + mandatory $99/mo Alloy Weight Care fee = $199/mo effective

Compounded liraglutide + Weight Care feeCompounded
$214/mo
liraglutide

$115 medication + mandatory $99/mo Alloy Weight Care fee = $214/mo effective

Brand Wegovy + Weight Care fee (starting)Brand-name
$298/mo
Wegovy

$199-$499 medication + mandatory $99/mo Alloy Weight Care fee; $298/mo effective at the $199 starting dose

Brand Zepbound + Weight Care fee (starting)Brand-name
$398/mo
Zepbound

$299 medication + mandatory $99/mo Alloy Weight Care fee = $398/mo effective

NowPatient

Mounjaro (brand, cash-pay)Brand-name
$1069/mo
tirzepatide
Wegovy injection (brand, cash-pay)Brand-name
$1349/mo
semaglutide
Wegovy oral tablet (brand, cash-pay)Brand-name
$1349/mo
semaglutide
Saxenda (brand, cash-pay)Brand-name
$1349/mo
liraglutide

What each price covers

NowPatient's price also covers the clinician visit and the medication itself, which Alloy does not claim.

Alloy does not say what its price includes.

NowPatient is silent on shipping, lab work and coaching.

That matters most for the drug: unless Alloy confirms otherwise, budget for medication on top of its listed price.

Alloy

Inclusions not disclosed.

NowPatient

Covered by the monthly price

Medication

In the price

Clinician visits

In the price

Shipping

Not stated

Lab work

Not stated

Coaching

Not stated

Where each one scores higher

Overall, Alloy scores 6.2 and NowPatient 6.1 out of 10.

Alloy is stronger on value (6.6 vs 6.1) and user experience (3.0 vs 2.5).

NowPatient is stronger on support (5.5 vs 5.0).

Effectiveness, trust & safety and accessibility are within half a point.

How we score

Alloy

6.2/10

Overall

NowPatient

6.1/10

Value25%

6.6A
vs
B
6.1

Effectiveness25%

10.0A
vs
B
10.0

User Experience15%

3.0A
vs
B
2.5

Trust & Safety15%

4.0A
vs
B
4.0

Accessibility10%

5.0A
vs
B
5.0

Support10%

5.0A
vs
B
5.5

FDA warning letters

Neither Alloy nor NowPatient has an FDA warning letter on record with us.

Features & Coverage

FeatureAlloyNowPatient
Starting Price✓$169/mo$1,069/mo
Features✓8 features2 features
States AvailableNot disclosedNot disclosed
Compounded✓ Yes—
Brand Name✓ Yes✓ Yes
FSA/HSA Accepted——
FDA Warning LettersNoneNone

About Alloy

Alloy centers on menopause, and its Weight Care program lists a GLP-1 formulary no other entry in our catalog matches for breadth. On the brand side: Wegovy, Zepbound, and oral Wegovy. Compounded: semaglutide, tirzepatide, liraglutide. Prices span from $199/mo for brand Wegovy down to $80/mo for compounded liraglutide. The first consult costs $49, and the code STARTGLP1 cuts $50 from month one. The Menopause Society has certified every doctor who consults there.

Read our full Alloy review →

About NowPatient

Nothing is charged for the consultation at NowPatient; the medication is the whole bill. Because the out-of-pocket cost tracks brand list prices, an uninsured patient faces roughly $1,000-$1,350/mo. Access is to brand-name GLP-1s for weight management: Saxenda is on the menu, so is Mounjaro, and Wegovy comes as an injection and as an oral tablet. The company spans the US and UK, HQ Austin, TX.

Read our full NowPatient review →

Pros & Cons

Alloy

What we like

  • Semaglutide costs $169 a month, close to the $185 median for compounded semaglutide across the sellers we compare
  • Tirzepatide costs $199 a month, 20% below the $250 median for compounded tirzepatide across the sellers we compare
  • We found no FDA warning letters issued to Alloy

Watch-outs

  • You only see a price after finishing the medical intake, so you cannot compare costs before sharing health information
  • Confirm it serves your state before you start the intake
  • Ask which pharmacy fills the prescription before you pay, so you can check its license
  • Its liraglutide, semaglutide and tirzepatide are compounded rather than FDA-approved, so they have not been reviewed by the agency for safety, effectiveness or manufacturing quality

NowPatient

What we like

  • Tirzepatide costs $1069 a month, 14% below the $1249 median for brand-name tirzepatide across the sellers we compare
  • The monthly price includes the medication and clinician visits
  • We found no FDA warning letters issued to NowPatient
  • A live video visit with a clinician is required before a prescription, which is slower than a form and is the more careful intake

Watch-outs

  • Semaglutide costs $1349 a month, 35% above the $997 median for brand-name semaglutide across the sellers we compare
  • You only see a price after finishing the medical intake, so you cannot compare costs before sharing health information
  • Confirm it serves your state before you start the intake
  • Ask which pharmacy fills the prescription before you pay, so you can check its license

Our Verdict

Winner: Alloy

Alloy wins this one, 6.2 to 6.1, above all for compounded semaglutide at $169/month. It also costs $900 less each month than NowPatient. NowPatient fits better if an oral route if you will not self-inject is your priority.

Choose Alloy if…

You want compounded semaglutide at $169/month and an opening price near $169 a month.

Choose NowPatient if…

You want an oral route if you will not self-inject and an opening price near $1,069 a month.

Ready to start? GLP-1 providers we have vetted

Telehealth providers, vetted by us, prescribing GLP-1 online.

Vetted by our editors · no insurance required

Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more

8.4

Strut Health

Semaglutide at $99/month, 48% below the typical price

8.4

Enhance MD

Knowing which pharmacy fills the vial: it names Tru Meds Rx

6.1

DudeMeds

Compounded semaglutide at $175/month

Alloy vs NowPatient: FAQ

Alloy. It starts at $169 a month; NowPatient starts at $1,069 a month, $900 more per month.
Yes, both sell semaglutide, tirzepatide and liraglutide.
Alloy does not publish where it ships; NowPatient does not publish where it ships. Confirm your state before paying.
Only NowPatient includes the clinician visit and the medication itself.
Alloy has none. NowPatient has none.
No. Neither Alloy nor NowPatient pays us anything.

Or see the full category ranking.

Novo Nordisk A/S owns the Wegovy®, Ozempic® and Rybelsus® marks; Eli Lilly and Company owns Mounjaro® and Zepbound®. Every other product name and mark on this page belongs to whoever owns it. No pharmaceutical manufacturer is affiliated with GLP Watchdog. See trademark disclaimer.